Moderna 2022 Priorities and Capital Allocation

2022 financial framework Sales Cost of sales For expected delivery in FY 2022: Advance Purchase Agreements (APAs) currently signed for product sales of ~$21 billion We continue to expect sales to be larger in the second half of 2022 than in the first half as SARS-CoV-2 becomes endemic We continue to expectfull year 2022 reported cost of sales in the low-to-mid 20s percentage range R&D and SG&A Expenses We continue to expectfull year R&D and SG&A expenses of approximately $4 billion Tax rate We continue to expect an effective tax rate for the full year in the mid-teen percentage range Capital Expenditures We continue to expect capital expenditures in the range of $0.6-$0.8 billion Slide 34 moderna

View entire presentation